These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 19000363

  • 1. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery.
    Gordon S, Saupe A, McBurney W, Rades T, Hook S.
    J Pharm Pharmacol; 2008 Dec; 60(12):1591-600. PubMed ID: 19000363
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery.
    Gordon S, Teichmann E, Young K, Finnie K, Rades T, Hook S.
    Eur J Pharm Sci; 2010 Oct 09; 41(2):360-8. PubMed ID: 20633644
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S.
    Int J Pharm; 2008 Nov 03; 363(1-2):139-48. PubMed ID: 18662762
    [Abstract] [Full Text] [Related]

  • 5. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.
    Sexton A, Whitney PG, Chong SF, Zelikin AN, Johnston AP, De Rose R, Brooks AG, Caruso F, Kent SJ.
    ACS Nano; 2009 Nov 24; 3(11):3391-400. PubMed ID: 19824668
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
    San Román B, Irache JM, Gómez S, Tsapis N, Gamazo C, Espuelas MS.
    Eur J Pharm Biopharm; 2008 Sep 24; 70(1):98-108. PubMed ID: 18501572
    [Abstract] [Full Text] [Related]

  • 8. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
    Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W.
    J Control Release; 2006 Mar 10; 111(1-2):107-16. PubMed ID: 16380189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
    Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, Bouwstra J, Broere F, Jiskoot W.
    Vaccine; 2010 Aug 31; 28(38):6282-91. PubMed ID: 20638455
    [Abstract] [Full Text] [Related]

  • 11. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
    Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE.
    J Control Release; 2011 Nov 30; 156(1):46-52. PubMed ID: 21784113
    [Abstract] [Full Text] [Related]

  • 12. Carbohydrate modified ultrafine ceramic nanoparticles for allergen immunotherapy.
    Pandey RS, Sahu S, Sudheesh MS, Madan J, Kumar M, Dixit VK.
    Int Immunopharmacol; 2011 Aug 30; 11(8):925-31. PubMed ID: 21333772
    [Abstract] [Full Text] [Related]

  • 13. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
    Slütter B, Soema PC, Ding Z, Verheul R, Hennink W, Jiskoot W.
    J Control Release; 2010 Apr 19; 143(2):207-14. PubMed ID: 20074597
    [Abstract] [Full Text] [Related]

  • 14. Modified thermoresponsive Poloxamer 407 and chitosan sol-gels as potential sustained-release vaccine delivery systems.
    Kojarunchitt T, Baldursdottir S, Dong YD, Boyd BJ, Rades T, Hook S.
    Eur J Pharm Biopharm; 2015 Jan 19; 89():74-81. PubMed ID: 25481034
    [Abstract] [Full Text] [Related]

  • 15. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles?
    Slütter B, Bal SM, Que I, Kaijzel E, Löwik C, Bouwstra J, Jiskoot W.
    Mol Pharm; 2010 Dec 06; 7(6):2207-15. PubMed ID: 21043518
    [Abstract] [Full Text] [Related]

  • 16. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
    Prego C, Paolicelli P, Díaz B, Vicente S, Sánchez A, González-Fernández A, Alonso MJ.
    Vaccine; 2010 Mar 19; 28(14):2607-14. PubMed ID: 20096389
    [Abstract] [Full Text] [Related]

  • 17. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice.
    Jiang L, Qian F, He X, Wang F, Ren D, He Y, Li K, Sun S, Yin C.
    J Gene Med; 2007 Apr 19; 9(4):253-64. PubMed ID: 17397104
    [Abstract] [Full Text] [Related]

  • 18. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

  • 19. Chitosan/sulfobutylether-β-cyclodextrin nanoparticles as a potential approach for ocular drug delivery.
    Mahmoud AA, El-Feky GS, Kamel R, Awad GE.
    Int J Pharm; 2011 Jul 15; 413(1-2):229-36. PubMed ID: 21540097
    [Abstract] [Full Text] [Related]

  • 20. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors.
    Bilensoy E, Sarisozen C, Esendağli G, Doğan AL, Aktaş Y, Sen M, Mungan NA.
    Int J Pharm; 2009 Apr 17; 371(1-2):170-6. PubMed ID: 19135514
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.